Trial Profile

A phase 2a study of AZP-3601 for treatment of hypoparathyroidism

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 02 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eneboparatide (Primary)
Indications Hypoparathyroidism
Focus Proof of concept; Therapeutic Use

Most Recent Events

15 Jul 2024 According to an Amolyt Pharma media release, Amolyt Pharma has been acquired AstraZeneca.
27 Sep 2023 According to an Amolyt Pharma media release, data from this study will be presented at at the 39th Congress of the French Society of Endocrinology, being held October 4-7, 2023, in Marseille, France
18 Jun 2023 Results (n=24) assessing the effects of AZP-3601 on urinary Ca (uCa) excretion in two consecutive cohorts (C1 and C2) of cHP patients presented at the 105th Annual Meeting of the Endocrine Society

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com